Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Raptor Pharma (RPTP) Completes Cash, Stock Acquisition of Quinsair
October 5, 2015 7:28 AM EDTRaptor Pharma (NASDAQ: RPTP) announced that it has completed the acquisition of Quinsair (levofloxacin inhalation solution) from Tripex Pharmaceuticals. Quinsair is the first inhaled fluoroquinolone antibiotic approved in the European Union and in Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis.
"The acquisition of Quinsair adds another significant product to our rare disease... More
